Pelvic bone loss may contribute to pelvic stress fracture after hip replacement

Translate to Spanish or other 102 languages!

Total hip replacement may affect the development of a type of pelvic stress fracture, sacral insufficiency fracture (SIF), suggests a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer. Image for illustration purposes
Total hip replacement may affect the development of a type of pelvic stress fracture, sacral insufficiency fracture (SIF), suggests a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer. Image for illustration purposes

Mega Doctor News

- Advertisement -

By Wolters Kluwer Health: Lippincott

Newswise – Total hip replacement may affect the development of a type of pelvic stress fracture, sacral insufficiency fracture (SIF), suggests a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.

In particular, SIF appears more likely to occur on the side opposite from previous total hip arthroplasty (THA), according to the new research by Dr. Isabel Graul and colleagues of University of Jena, Eisenberg, Germany. The study also provides evidence that loss of bone density leading to SIF begins within the first postoperative year following THA.

- Advertisement -

Study suggests ‘spatially different bone remodeling’ across the sacrum following THA

Sacral insufficiency fracture occurs as a result of decreased bone mineral density in the sacrum. These fractures most commonly occur in older women, causing low back pain that worsens with activity. SIF is becoming increasingly common as the population ages and live longer, leading to more patients with osteoporosis.

Although several risk factors for SIF have been identified, the role of THA is unclear. Dr. Graul and colleagues designed a two-part study to assess the influence of THA on the development and localization of SIF. In a review of 171 patients diagnosed with SIF, the researchers identified 50 patients with previous THA in one or both hips. The average age was 79 years, and 40 of the patients were women. On average, SIF developed about eight years after THA.

Among the 31 SIF patients who had undergone THA in just one hip, the SIF was located in the opposite side twice as often as in the operative side (42 percent compared with 19 percent, respectively). The remaining 39 percent of patients developed SIF on both sides of the pelvis.

- Advertisement -

In the second part of the study, the researchers analyzed 39 patients with initially healthy bone mineral density who underwent THA. Changes in bone density were assessed in computed tomography scans performed at 1 year after THA. The results showed a small but significant reduction of bone mineral density in the sacrum, but only on the side opposite from the THA. There was no significant change in bone mineral density in the sacrum on the same side as the THA.

Over time, THA may lead to “spatially different bone remodeling,” as a result of changes in load transmission through the pelvis, Dr. Graul and colleagues write. The authors note that a key question remains unresolved: does THA cause decreased bone loss on the opposite side of the sacrum, or does it prevent bone loss on the same side of the sacrum. The researchers conclude, “additional studies focusing on this remodeling process, and assessing different implant designs and longer-term changes, are needed.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.

DHR Health Burn Surgeon Urges Public to Avoid Preventable Risks

Many of the most serious burn and trauma injuries can be prevented by avoiding unnecessary risks, according to Dr. R. Dewayne Edwards, chief burn surgeon, surgical critical care and trauma surgeon at DHR Health, who said public awareness and timely medical care remain essential to improving patient outcomes.
- Advertisement -